Future Oncology

Article	Citations
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up	100
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	80
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	69
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	61
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	57
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	47
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice	46
Sex bias phenomenon in oral cancer: an insight	46
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	44
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	43
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer	43
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	42
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	42
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	41
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE	40
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	38
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	37
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	37
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	36
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	35
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	34
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	32
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	32
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	32
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?	32

The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	32
DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy	32
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma	31
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma	30
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	29
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	29
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	28
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	28
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database	27
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges	27
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients	26
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer	26
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)	26
Serum Exosomal miR-377-3p and miR-381-3p as Diagnostic Biomarkers in Colorectal Cancer	25
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study	25
The treatment of advanced pulmonary sarcomatoid carcinoma	25
Treatment Patterns and Overall Survival in HER2+ Metastatic Breast Cancer at US Community Oncology Practices	25
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design	25
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer	25
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis	25
A Multicenter Randomized, Controlled Clinical Trial of Adjuvant Sintilimab for Esophageal Squamous Cell Carcinoma	24
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis	24
Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study	24
Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer	24
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer	23
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review	23
Real-World Cost–Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High Risk of Febrile Neutropenia	23
Pembrolizumab: First Adjuvant Immunotherapy in Renal Cell Carcinoma?	23
A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study	22
The ‘Hit-and-Run’ Strategy and Viral Carcinogenesis	22
Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition	22
Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?	22
Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-	22
Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database	22
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer	22
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma	22
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer	21
Association of human papillomavirus with breast cancer: a new perspective on an old debate	21
An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection	21
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping	21
Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses	21
LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma	20
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment	20
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review	20
Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma	20
The Benefit of Immunotherapy in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	19
Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US	19
Multimodal Analysis of ctDNA Methylation and Fragmentomic Profiles Enhances Detection of Nonmetastatic Colorectal Cancer	19
Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland	19
Preferences for First-Line Treatment of Advanced Urothelial Carcinoma among US Practicing Oncologists and Patients	19

Effect of preoperative peripheral blood platelet volume index on prognosis in patients with invasive breast cancer	18
As a Potential Predictor of Pan-Cancer, UBE2S is Related to Tumor-Associated Macrophage Infiltration	18
Application and Prospect of Single-Cell Sequencing in Cancer Metastasis	18
Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice	18
G-CSF and G-CSF-Related Vasculitis: A Systematic Review of the Literature and Intriguing Future Research Perspectives	17
Lorlatinib as a treatment for ALK-positive lung cancer	17
Next-Generation Sequencing of Cancer Genomes: Lessons Learned	17
Does Failed Mapping Predict Sentinel Lymph Node Metastasis in cN0 Breast Cancer?	17
Intraperitoneal Infusion of Recombinant Human Endostatin Improves Prognosis in Gastric Cancer Ascites	17
Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers	17
Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA	17
The Importance of the Glucose-To-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Treated with Sorafenib	17
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC tri	17
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission	17
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study	16
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients	16
Analysis of the Expression Patterns and Clinical Relevance of m 6 A Regulators in 33 Cancer Types	16
Correction	16
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: A Plain Language Summary Of The DESTINY-Gastric01 Study	16
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer	16
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada	16
Relationship Between Nurses’ Perceptions and Financial Toxicity Management in the Public Health Insurance System	16
Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors	15
Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection	15
Corrigendum	15
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer	15
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a	15
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis	15
Deep learning-based multiomics integration model for predicting axillary lymph node metastasis in breast cancer	14
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients	14
Co-expression of CD44v6 and MMP2 predicts lung metastasis and unfavorable prognosis in osteosarcoma	14
The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index	14
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia	14
Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study	14
Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey	14
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies	13
Plain language summary and patient perspective of the revised STARS study: long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung ca	13
CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel Disease-Specific MRI Measures of Tumor Burden	13
Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study	13
Pediatric oncohematological exercise program in hospital: clinical trial study protocol	13
A Critical Appraisal on Cancer Prognosis and Artificial Intelligence	13
Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic	13
Clinical Effectiveness of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation For Lack of Blood Supply in Hepatocellular Carcinoma	13
Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers	12
Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database	12
Exploring the Connection Between Microsatellite Instability and Inflammatory Indicators in Cancers	12
Expanded Access to Anticancer Treatments from Conversion to Biosimilar Pegfilgrastim-cbqv in US Breast Cancer Patients	12
Guideline Conformity to the Stupp Regimen in Patients with Newly Diagnosed Glioblastoma Multiforme in China	12
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer	12
Predictors of Poor Precautionary Practices Towards COVID-19 Among Cancer Patients	12
Construction of methylation-associated nomogram for predicting the recurrence-free survival risk of stage I–III lung adenocarcinoma	12
Outdoor air pollution and oral cancer: critical viewpoints and future prospects	12
Hypersensitivity Reactions to Asparaginase Therapy in Acute Lymphoblastic Leukemia: Immunology and Clinical Consequences	12
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial	12
Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants	11
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma	11
Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation	11
The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy	11
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma	11
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel	11
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells	11
Gastric cancer in pregnancy: a review	11
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?	11
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study	11
A real-world evaluation of the rapid diagnostic clinic roll out in South East London	11
Systematic Literature Review of Current Treatments for Stage I–III Merkel Cell Carcinoma	11
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey	11
Temporal Trends of Adverse Events and Costs of Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal Cell Carcinoma	11
Detection and Verification of Coexisting Diagnostic Markers in Plasma and Serum of Patients with Non-Small-Cell Lung Cancer	11
Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary	11
Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia	11
Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway	10
NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer	10
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy	10
Perspective on the Risk of Suicide Associated with Oral Cancer Diagnosis	10
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma	10
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies	10
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study	10
Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer	10
Palliative and End-Of-Life Symptoms Management for Children with Diffuse Intrinsic Pontine Glioma	10

Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey	10
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resist	10
Benefit-Risk Trade-Offs in Treatment Choice in Advanced HER2 Negative Breast Cancer: Patient and Oncologist Perspectives	10
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma	10
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma	10
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary	10
Tebentafusp for the Treatment of Metastatic Uveal Melanoma	10
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis	10
Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors	10
Unsupervised Learning of Cross-Modal Mappings in Multi-Omics data for Survival Stratification of Gastric Cancer	10
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?	10
Real-World Outcomes of Pomalidomide Therapy after Lenalidomide Induction in Relapsed/Refractory Multiple Myeloma	9
Methylation site APC 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence	9
Real-world Management Patterns in EGFR -mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece	9
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma	9
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)	9
Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA	9
Safety and efficacy of left colic artery preservation in laparoscopic anterior resection for lower rectal cancer	9
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA	9
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary	9
Research progress on the role of lipoxygenase and its inhibitors in prostate cancer	9
Retrospective study of total neoadjuvant therapy for locally advanced rectal cancer	9
Improved Outcomes and Staging in Non-Small-Cell Lung Cancer Guided by A Molecular Assay	9
Value of Biomarkers in Epithelial–Mesenchymal Transition Models Of Liver Cancer Under Different Interventions: A Meta-Analysis	9
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021	9
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study	9
Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma	9
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis	9
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer	9
Methylated ZNF582 as a triage marker for occult cervical cancer and advanced cervical intraepithelial neoplasia	9
Association of Polymorphisms in PIN1 with Progression And Susceptibility in Gastric Cancer	9
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale	9
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis	9
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion	9
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence	9
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer	9
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma	8
Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey	8
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population	8
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases	8
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma	8
Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule	8
The Management of a Breast Unit During the COVID-19 Emergency: A Local Experience	8
Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis	8
Extended distal pancreatectomy in pancreatic cancer: is it justified? A systematic review of literature	8
Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer	8
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?	8
Correction	8
Clinical Application of Serum Tumor Abnormal Protein Combined with Tumor Markers in Lung Cancer Patients	8
Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked	8
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma	8
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial	8
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006	8
Development and validation of a Cancer Patient Suicidal Ideation Scale	8
Characterization of the immune environment in pregnancy-associated breast cancer	8
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy	8
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101	8
Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma	8
The Role of Surgery in Metastatic Cancer: The Case For a Pragmatic Tumor-Agnostic Randomized Trial	8
PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer	8
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations	8
Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force	8
Prognostic Value of GPC5 Polymorphism rs2352028 and Clinical Characteristics in Chinese Lung Cancer Patients	8
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review	8
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	7
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe	7
An Interview with Ginny Mason: 20 Years of Kicking Butt and Taking Names	7
A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide	7
Exploring Exosome Data to Identify Prognostic Gene Signatures for Lung Adenocarcinoma	7
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	7
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary	7
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study	7
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences	7
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data	7
The Implications from the Interplay of Neoadjuvant Chemoradiotherapy and the Immune Microenvironment in Rectal Cancer	7
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer	7
Financial Toxicity and its Impact on Health Outcomes and Caregiver Burden Among Adult Cancer Survivors in the USA	7
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success	7
Selpercatinib in the treatment of thyroid cancer	7
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?	7
Margetuximab in HER2-positive metastatic breast cancer	7
siRNA-Based Approaches for Castration-Resistant Prostate Cancer Therapy Targeting the Androgen Receptor Signaling Pathway	7
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China	7
Frontline anti-PD-1/PD-L1 Versus Bevacizumab in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis	7
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	7
Corrigendum	7
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study	7
Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small-cell lung cancer	7
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma	7
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial	7
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	7
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	7
ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers	7
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer	7
The impact of myelosuppression on quality of life of patients treated with chemotherapy	7